CD274 and neoplasm: With the remarkable clinical success of immune checkpoint inhibitors in several refractory tumours, PD-1 and its ligand PD-L1 have generated increasing interest in exploring potential treatment targets and promising biomarkers in glioma therapies [20], [21].